CRISPR Therapeutics AG
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CRISPR Therapeutics AG | ||
| Date: February 21, 2024 | By: | /s/ Samarth Kulkarni |
|---|---|---|
| Samarth Kulkarni | ||
| Chief Executive Officer | ||
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned directors and officers of CRISPR Therapeutics AG (the “Company”), hereby severally constitute and appoint Samarth Kulkarni, Raju Prasad and James R. Kasinger, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Samarth Kulkarni | Chief Executive Officer, Chairman and Director | February 21, 2024 |
| Samarth Kulkarni | (Principal Executive Officer) | |
| /s/ Raju Prasad | Chief Financial Officer | February 21, 2024 |
| Raju Prasad | (Principal Financial and Accounting Officer) | |
| /s/ Ali Behbahani | Director | February 21, 2024 |
| Ali Behbahani | ||
| /s/ Maria Fardis | Director | February 21, 2024 |
| Maria Fardis | ||
| /s/ H. Edward Fleming, Jr. | Director | February 21, 2024 |
| H. Edward Fleming, Jr. | ||
| /s/ Simeon J. George | Director | February 21, 2024 |
| Simeon J. George | ||
| /s/ John Greene | Director | February 21, 2024 |
| John Greene | ||
| /s/ Katherine High | Director | February 21, 2024 |
| Katherine A. High | ||
| /s/ Douglas Treco | Director | February 21, 2024 |
| Douglas A. Treco | ||
| /s/ Raju Prasad | Authorized Representative in the United States | February 21, 2024 |
| Raju Prasad | ||
| Index to Consolidated Financial Statements | Pages |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42) | F-1 |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive (Loss) Income | F-4 |
| Consolidated Statements of Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.